Brokers Offer Predictions for CGTX FY2025 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Research analysts at Brookline Capital Acquisition issued their FY2025 earnings estimates for shares of Cognition Therapeutics in a report released on Tuesday, February 3rd. Brookline Capital Acquisition analyst F. Ahmed anticipates that the company will post earnings per share of ($0.35) for the year. Brookline Capital Acquisition has a “Strong-Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Brookline Capital Acquisition also issued estimates for Cognition Therapeutics’ Q4 2025 earnings at ($0.06) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.26) EPS and FY2026 earnings at ($0.46) EPS.

Other equities analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Cognition Therapeutics in a research note on Thursday, December 4th. Wall Street Zen raised Cognition Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, December 29th. Brookline Cap M raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday. Finally, B. Riley Financial restated a “buy” rating and issued a $3.00 price target (up from $2.00) on shares of Cognition Therapeutics in a research note on Friday, November 21st. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $3.33.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $1.06 on Friday. The firm has a 50 day simple moving average of $1.44 and a two-hundred day simple moving average of $1.56. Cognition Therapeutics has a one year low of $0.22 and a one year high of $3.83. The company has a market cap of $93.57 million, a P/E ratio of -2.21 and a beta of 1.25.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01.

Hedge Funds Weigh In On Cognition Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its holdings in shares of Cognition Therapeutics by 814.1% during the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after purchasing an additional 897,353 shares during the period. DAVENPORT & Co LLC bought a new position in Cognition Therapeutics during the 3rd quarter worth $3,631,000. CWA Asset Management Group LLC acquired a new position in Cognition Therapeutics during the 3rd quarter worth about $34,000. McAdam LLC bought a new stake in shares of Cognition Therapeutics in the 3rd quarter valued at about $97,000. Finally, Bryn Mawr Trust Advisors LLC increased its stake in shares of Cognition Therapeutics by 69.1% in the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after buying an additional 16,129 shares during the period. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cognition Therapeutics

Here are the key news stories impacting Cognition Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded CGTX to “Strong‑Buy” and released a set of quarterly and full‑year EPS estimates that are less negative than market consensus (Brookline FY2026: -$0.46 vs. consensus -$0.80). The upgrade plus narrower loss estimates likely improved investor expectations for future valuation and financing needs. Brookline coverage (MarketBeat)
• Positive Sentiment: Cognition extended the duration of its expanded access program (EAP) for Zervimesine (CT1812) in dementia with Lewy bodies, allowing enrolled patients additional months of treatment — a sign of ongoing clinical engagement and potential real‑world data generation that can de‑risk the program incrementally. GlobeNewswire: EAP extension
• Neutral Sentiment: Multiple Brookline research notes repeated the same forward‑looking quarterly estimates (Q4‑2025 through Q4‑2026) and the Strong‑Buy call — the breadth of published estimates helps set expectations but adds little new detail beyond the upgrade. Brookline coverage (MarketBeat)
• Negative Sentiment: Despite the more favorable forecasts from Brookline, Cognition remains a clinical‑stage company with no approved products and ongoing projected losses (consensus FY current year ~ -$0.80 EPS). That keeps the stock exposed to clinical, regulatory and financing risk, which can drive volatility and dilution. Market context (MarketBeat)

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.